BLOG

Thursday, April 25, 2019

Targeted therapy proves effective against aggressive rare blood cancer

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.

from Top Health News -- ScienceDaily http://bit.ly/2UVNFlS
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...